Earnings Call Excerpt
Merck & Co. Inc. (MRK)
Q2 2009 Earnings Call
July 21, 2009 8:30 am ET
Executives
Eva Boratto – Vice President of Investor Relations
Richard T. Clark – Chairman, President and Chief Executive Officer
Kenneth C. Frazier – Executive Vice President and President – Global Human Health
Peter N. Kellogg – Chief Financial Officer, Executive Vice President
Bruce N. Kuhlik – Executive Vice President, General Counsel
Peter S. Kim Ph.D. – Executive Vice President and President – Merck Research Laboratories
Analysts
Tim Anderson – Sanford Bernstein
Chris Schott – JP Morgan
Jami Rubin – Goldman Sachs
John Boris – Citigroup
David Reisinger – Morgan Stanley
[Quyeor Purique] – UBS
Tony Butler – Barclays Capital
Seamus Fernandez – Leerink Swan
Steve Scala – Cowen and Company
Presentation
Operator
Welcome to Merck's second quarter 2009 earnings conference call. (Operator Instructions) At this time I would like to turn the call over to Miss Eva Boratto, Vice President of Investor Relations. Please go ahead, ma'am.
Eva Boratto
Welcome to our call to review our business performance for the second quarter of 2009. Joining me on the call today are, as always, our Chairman, President and CEO, Dick Clark, Ken Frazier, our Executive Vice President and President Global Human Health, and Peter Kellogg, our Executive Vice President and Chief Financial Officer. Also here on the call to participate in the Q&A is Bruce Kuhlik, Executive Vice President and General Counsel.
Before we get into the details I'd like to go over some logistics. On this call we will review the results contained in the release we issued at 7:00 am this morning. You can access this through the Investor Relations section on merck.com and I will remind you that this conference call is being Webcast live and recorded. The replay of this event will be available later today via phone, Webcast and Podcast.
As we begin our review let me remind you that some of the statements made during this call may discuss certain subjects that may contain forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties which may cause results to differ materially from those set forth in the statements.
The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed and any actual result may differ materially from those projected. Merck undertakes no obligation to publicly update any forward-looking statements whether as a result of new information, future events or otherwise.
- To read the full transcript on Seeking Alpha, click here »
